Pierluigi Porcu, MD
Hematology & Oncology · Philadelphia, PANPI 1376551564
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Sobi, Inc at 50.3% of the total. Reporting peaked in 2024 at $58,879 and has fallen 95.2% since, to $2,849 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 78 payments — averaging $1358.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$53K
- Kyowa Kirin, Inc.$19K
- Daiichi Sankyo Inc.$11K
- Eli Lilly$8K
- Morphosys AG$5K
- Innate Pharma, Inc$4K
- plus $5K from 8 others
Across 70 payments — averaging $11,581 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$504K
- Genentech, Inc.$260K
- Morphosys AG$17K
- Innate Pharma, Inc$13K
- Bristol Myers Squibb$11K
- Incyte Corporation$6K
What the payments were for
- Consulting fees$56,33753%
- Speaking & faculty fees$41,57039%
- Travel & lodging$5,2265%
- Food & beverage$2,7893%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 32 | $53,260 |
| Kyowa Kirin, Inc. | 13 | $19,132 |
| Daiichi Sankyo Inc. | 9 | $11,210 |
| Eli Lilly | 7 | $8,100 |
| Morphosys AG | 3 | $4,968 |
| Innate Pharma, Inc | 1 | $3,900 |
| ADC Therapeutics America, Inc. | 2 | $2,800 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,438 |
| Teva Pharmaceuticals USA, Inc. | 1 | $650 |
| Genentech, Inc. | 3 | $323 |
| Adaptive Biotechnologies Corporation | 1 | $74 |
| Genentech USA, Inc. | 1 | $46 |
| Servier Pharmaceuticals LLC | 3 | $33 |
| Johnson & Johnson | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,955 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Philadelphia
- Henry FungPhiladelphia$730K
- Charu AggarwalPhiladelphia$541K
- Corey LangerPhiladelphia$492K
- Ankur ParikhPhiladelphia$329K
- Catherine LaiPhiladelphia$281K
- Stephen SchusterPhiladelphia$218K
- Keith PratzPhiladelphia$173K
- David PorterPhiladelphia$140K
- Adam BinderPhiladelphia$136K
- Marcela MausPhiladelphia$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.